Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Account Payables: 2013-2025

Historic Change in Account Payables for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$5.0 million.

  • KalVista Pharmaceuticals' Change in Account Payables fell 122.83% to -$1.4 million in Q2 2025 from the same period last year, while for Apr 2025 it was $348,000, marking a year-over-year decrease of 91.94%. This contributed to the annual value of -$5.0 million for FY2025, which is 215.07% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Change in Account Payables stood at -$5.0 million for FY2025, which was down 215.07% from $4.3 million recorded in FY2024.
  • In the past 5 years, KalVista Pharmaceuticals' Change in Account Payables ranged from a high of $4.3 million in FY2024 and a low of -$5.0 million during FY2025.
  • Over the past 3 years, KalVista Pharmaceuticals' median Change in Account Payables value was $1.1 million (recorded in 2023), while the average stood at $152,000.
  • In the last 5 years, KalVista Pharmaceuticals' Change in Account Payables spiked by 1,024.67% in 2022 and then slumped by 215.07% in 2025.
  • KalVista Pharmaceuticals' Change in Account Payables (Yearly) stood at $150,000 in 2021, then skyrocketed by 1,024.67% to $1.7 million in 2022, then slumped by 34.38% to $1.1 million in 2023, then soared by 290.24% to $4.3 million in 2024, then slumped by 215.07% to -$5.0 million in 2025.